Molnlycke Health Care Acquires the Burn and Wound Care Business From Brennen Medical

Molnlycke Health Care Acquires the Burn and Wound Care Business From Brennen Medical
 

NORCROSS, Ga., Feb. 24, 2012 /PRNewswire/ -- Molnlycke Health Care US, LLC, a wholly-owned subsidiary of Molnlycke Health Care AB (Gothenburg, Sweden) announces it has acquired the assets of Brennen Medical (St. Paul, MN) associated with their business in Burn and Wound Care.

In this transaction (terms not disclosed), Molnlycke Health Care US, LLC has acquired all the Commercial Assets of Brennen Medical within the Burn and Wound Care markets. Brennen Medical will under a new name continue to develop their core technologies (porcine tissue and beta-glucans) for applications in other markets.

For nearly 40 years, Brennen Medical has been a trusted supplier to the Burn and Wound Care community with their products covering the following three main areas:

Porcine xenograft tissue - for temporary coverage for severe burns
Beta-glucan creams, gels and dressings – to aid in healing more superficial burns
Ancillary burn care products including graft meshers, silicone gel scar sheets and other supplies.
These products have been effectively used in leading hospitals and burn centers in the US, Canada and select European markets.

"Combining Brennen Medical's 'best-in-class' products with our own market leading wound care brands will provide Molnlycke Health Care customers with a comprehensive range of technologically advanced and clinically proven burn and wound care solutions," says Barbara Osborne, President, US Wound Care for Molnlycke Health Care.

 

For further information please contact:
Molnlycke Health Care: Ann-Kathrin Halvorsen, Corporate Communications Director,
[email protected] / +46 31 7223058
Brennen Medical: Philip Lawin, President, [email protected] / 1-800-328-9105

 

About Molnlycke Health Care AB
Molnlycke Health Care is a world leading manufacturer of single-use surgical and wound care products and services for the professional health care sector.

The Surgical Division offers safe and efficient surgical solutions through a number of services and a wide range of high quality single-use surgical products that help minimise the risk of postoperative wound infections for patients, and create cumulative time, effort, and cost efficiencies.

The Wound Care division offers a wide range of wound care solutions, including products with Safetac® technology and the Avance® Negative Pressure Wound Therapy System, providing gentle and effective wound healing to patients and caregivers. The wound care assortment also has supplementary portfolios in compression, dermatology, and orthopedics as well as a product for hard-to-heal wounds.

About Brennen Medical, LLC
Brennen Medical is a world leader providing biologic porcine xenograft for use in plastic reconstructive, general surgery, burn, trauma, wound, urogynecological and orthopedic soft tissue repair procedures. Demonstrated to be effective, surgeons have used Brennen's proprietary porcine technologies for over 40 years. Mediskin® and EZ Derm®, Glucan Pro and Brennen Skin Meshers have been a staple in burn care for through that time.
Based in St. Paul, MN and privately held, the products are sold through a direct sales force and through partnerships with major medical device companies.

Press information Molnlycke Health Care US, LLC
5550 Peachtree Parkway
Suite 500
Norcross, GA 30092
USA
Phone +1 678 250 7900
Fax +1 678 250 7984
www.molnlycke.com

SOURCE Molnlycke Health Care US, LLC

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.